Zolmitriptan

Drug Profile

Zolmitriptan

Alternative Names: 311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomig-ZMT; Zomigon

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Burroughs Wellcome
  • Developer AstraZeneca; Impax Pharmaceuticals
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Menstrual migraine; Migraine

Most Recent Events

  • 30 Oct 2017 Zolmitriptan licensed to Sawai in Japan
  • 07 Jun 2017 Zolmitriptan licensed to Grunenthal worldwide (excluding Japan) for the treatment of migraines and cluster headaches
  • 30 Mar 2017 US District Court, District of Delaware, rules that the US patents protecting zolmitriptan Nasal Spray were not invalid and were infringed by the Lannett Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top